Market & Industry Trends - The Trump administration is reportedly planning to link Tylenol use during pregnancy to autism [1] - Autism rates in the US have increased significantly, affecting 1 in 31 children in 2022, up from 1 in 150 in 2000 [2] - Conflicting data exists regarding the link between Tylenol use and autism risk, with some studies suggesting a connection and others, controlling for genetics, finding no association [3] Company Performance & Stock Impact - Kenview shares are under pressure due to the reported link between Tylenol and autism [1] - Kenview stock was down approximately 7% on the day of the report and about 25% year-to-date [5] - Kenview strongly disagrees with any suggestion that acetaminophen causes autism, citing independent sound science [5] Regulatory & Public Health Implications - The administration may suggest pregnant women only take Tylenol for fevers, given the risks associated with fever during pregnancy [4] - Tylenol is the only pain reliever generally considered safe for use during pregnancy, making any recommendations potentially impactful [4]

Market Performance - All three major U.S. stock indices are in the green, with the Nasdaq up by 0.3% [1] - Notable stock performances include Oracle (ORCL.N) rising by 3.2%, Apple (AAPL.O) increasing by 3%, and Tesla (TSLA.O) gaining 3.9% [1] Company News - Kenvue, the producer of Tylenol, saw its stock drop over 4% ahead of the announcement from the Trump administration linking Tylenol use during pregnancy to autism in children, despite the company asserting no credible evidence supports this claim [2] - Nvidia has established its first AI technology center in the Middle East in collaboration with the Technology Innovation Institute (TII) in Abu Dhabi, focusing on the development of next-generation AI models and robotics [3] - Pfizer announced the acquisition of weight-loss drug manufacturer Metsera for a total deal value of up to $7.3 billion, with an initial payment of $47.50 per share and additional milestone payments based on clinical trial progress and FDA approvals [4] - Analysts report that despite complaints regarding the iPhone 17's susceptibility to scratches, this issue is not expected to impact Apple's sales or profitability [5] - Porsche has lowered its performance outlook for the fourth time this year, leading to a drop of over 7% in its stock price, which also negatively affected its major shareholder, Volkswagen [6] - Berkshire Hathaway has increased its stake in Mitsui & Co. to over 10%, indicating potential for further investment in the company [7]

Tylenol maker Kenvue 'strongly disagrees' there is a causal link between acetaminophen use during pregnancy and autism. ...

♪ VONNIE: GOOD MORNING, I’M VONNIE QUINN WITH YOUR BLOOMBERG BRIEF, HERE'S WHAT YOU NEED TO KNOW. FRESH RECORDS. FUTURES ARE POINTED LOWER AFTER INDICES CLOSED AT MORE ALL-TIME HIGHS FRIDAY.THE DOLLAR HAVING ITS WORST YEAR ON. -- YOU'RE ON RECORD. PRESIDENT TRUMP SIX-FIGURE H-1B HITS TAKE FROM AND INTERNATIONAL STUDENTS ALIKE.AND THE TRUMP ADMINISTRATION -- LINKING TYLENOL TO AUTISM. THEY ARE POINTED LOWER, PERHAPS A THE BIT RATE OPTIMISM FAILING OR A LITTLE BIT OF PROFIT-TAKING. 2.2% APIECE FOR THE NASDAQ ...

Group 1 - The Trump administration plans to announce a potential link between Tylenol use during pregnancy and autism [1][2] - Federal health officials are expected to advise against Tylenol use early in pregnancy unless necessary, while also highlighting leucovorin as a potential autism treatment [2] - Kenvue, the maker of Tylenol, experienced a sharp decline in shares following reports of the potential link to autism [3] Group 2 - Kenvue has stated that there is "no proven link" between acetaminophen and autism, and the CEO met with HHS Secretary Robert F. Kennedy Jr. to convey this message [4] - Kenvue executives noted the lack of safe alternatives to acetaminophen for fever reduction in pregnant women [5] - The FDA and leading medical organizations maintain that acetaminophen is safe during pregnancy when used as directed, advising consultation with healthcare providers [5]

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as one of the best dividend-paying stocks, with a strong dividend growth record and a market value nearing $425 billion [2][5]. Group 1: Financial Performance - In the second quarter, Johnson & Johnson reported a revenue increase of 5.8% year-over-year and an 18% rise in earnings [2]. - The company currently pays a quarterly dividend of $1.30 per share, resulting in a dividend yield of 2.95% as of September 19 [5]. Group 2: Business Structure - Until 2023, Johnson & Johnson had a robust consumer healthcare division, which included well-known products like Tylenol and Band-Aid, but this division has been spun off into a separate entity named Kenvue [3]. - Johnson & Johnson's diverse portfolio features immunology treatments such as Stelara and Tremfya, along with cancer medications like Darzalex and Erleada [4]. - The company is actively engaged in late-stage clinical trials, with 40 programs currently evaluating new drug candidates and seeking additional approvals for existing treatments [4].

Company Action - Kenvue contacted RFK Jr to prevent Tylenol from being listed as an autism-causing treatment [1]

Company Actions - Kenvue's CEO lobbied RFK Jr not to cite Tylenol as a potential cause of autism in an upcoming report [1]

Potential Link between Acetaminophen and Autism - An upcoming HHS report is expected to potentially link autism to pregnant women's use of acetaminophen [1] - The report will suggest folate as a way to decrease autism symptoms [1] - The report relies on existing studies and is expected to also suggest other potential causes for autism [2] - The science on the potential association between acetaminophen and autism is mixed [2] Company Stock and Stance - Shares of Ken View, the company that owns the maker of Tylenol, dropped approximately 10% [3] - Ken View believes there is no causal link between acetaminophen and autism [3] Expert Advice - Experts advise pregnant women to talk to their doctor about pain medicine [4] - Not taking pain medicine can put the mother and the fetus at risk [4] - The report indicates a potential link, not a definitive cause [4][5]

Core Viewpoint - Shares in Kenvue, the parent company of Tylenol-maker McNeil Consumer Healthcare, experienced a significant decline of over 14% following a report indicating a potential link between Tylenol and autism, as suggested by HHS Secretary Robert F. Kennedy Jr. [1][3] Group 1: Company Impact - Kenvue's shares plunged more than 14% in Friday afternoon trading due to the report [3] - The report is expected to be released this month and may highlight the risks associated with Tylenol taken during pregnancy [1] Group 2: Product Information - Tylenol is widely used for pain relief, fever reduction, and treating various symptoms, with acetaminophen as its active ingredient [2] - The medical community has previously deemed acetaminophen-containing products safe for pregnant women [2]